Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Leases (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Current Leases for 7 consecutive years, with $26.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 30.79% to $26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.5 million through Dec 2025, up 30.79% year-over-year, with the annual reading at $26.5 million for FY2025, 30.79% up from the prior year.
  • Current Leases for Q4 2025 was $26.5 million at Intellia Therapeutics, down from $27.4 million in the prior quarter.
  • The five-year high for Current Leases was $38.8 million in Q1 2025, with the low at $7.4 million in Q2 2021.
  • Average Current Leases over 5 years is $17.4 million, with a median of $16.9 million recorded in 2023.
  • The sharpest move saw Current Leases increased 8.86% in 2024, then soared 106.59% in 2025.
  • Over 5 years, Current Leases stood at $9.1 million in 2021, then skyrocketed by 83.11% to $16.7 million in 2022, then increased by 11.47% to $18.6 million in 2023, then grew by 8.86% to $20.2 million in 2024, then surged by 30.79% to $26.5 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $26.5 million, $27.4 million, and $27.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.